微創腦科學(02172.HK)公開發售獲超額認購45.27倍以上 預計7月15日掛牌上市
格隆匯7月14日丨微創腦科學(02172.HK)發佈公吿,公司全球發售1370萬股股份,其中香港發售股份411萬股,國際發售股份959萬股,另有15%超額配股權;每股發售股份24.64港元,每手買賣單位1000股;摩根大通及中金公司為聯席保薦人;預期股份將於2022年7月15日於聯交所主板掛牌上市。
香港公開發售提呈發售的發售股份相當大幅超額認購。合共接獲9320份有效申請,認購合共6201.7萬股,相當於香港公開發售項下初步可供認購香港發售股份總數約45.27倍以上。國際發售項下初步提呈發售的發售股份已獲輕微超額認購,相當於國際發售項下初步可供認購股份總數約2.14倍。按發售價每股24.64港元計算及根據基石投資協議,基石投資者已認購890.5萬股發售股份。
按發售價每股24.64港元計算並假設超額配股權未獲行使,將收取的全球發售所得款項淨額估計約為2.781億港元。公司擬將該等所得款項淨額約30.0%用於研發出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中治療及通路產品;約20.0%將用於出血性腦卒中、腦動脈粥樣硬化狹窄及急性缺血性腦卒中產品商業化;約15.0%將用於擴張製造設施以擴大生產規模;約20.0%將用於擴大公司全球影響力;約10.0%將用於透過戰略收購、投資、合作或該等戰略的結合以優化公司產品組合;及約5.0%將用作營運資金及其他一般公司用途。倘超額配股權獲悉數行使,將就配發及發行的205.5萬股額外股份收取額外所得款項淨額約4860萬港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.